Selective laser trabeculoplasty for early glaucoma: analysis of success predictors and adjusted laser outcomes based on the untreated fellow eye

Mikael Chun¹, Carolina P. B. Gracitelli¹*, Flavio S. Lopes¹,², Luis G. Biteli¹,², Michele Ushida² and Tiago S. Prata¹,²

Abstract

Background: To identify success predictors and to study the role of the fellow untreated eye as a co-variable for adjustment of intraocular pressure (IOP) outcomes following selective laser trabeculoplasty (SLT) in early open-angle glaucoma (OAG) patients.

Methods: A case series was carried out. Patients with uncontrolled early OAG or ocular hypertension (inadequate IOP control requiring additional treatment) underwent SLT (one single laser session) performed by the same surgeon in a standardized fashion. The same preoperative medical regimen was maintained during follow-up for all patients. Post-treatment assessments were scheduled at week 1 and months 1, 2, and 3. In order to account for possible influence of IOP fluctuation on laser outcomes, post-laser IOP values of the treated eye of each patient were also analyzed adjusting for IOP changes (between visits variation) of the untreated fellow eye (adjusted analysis). Pre and post-laser IOP values were compared using paired t-test. Factors associated with the magnitude of IOP reduction were investigated using multiple regression analysis.

Results: A total of 45 eyes of 45 patients were enrolled. Mean IOP was reduced from 20.8 ± 5.1 to 14.9 ± 2.9 mmHg at month 3 (p < 0.001). Adjusted success rate (defined as IOP reduction ≥ 20%) was 64% and mean percentage of IOP reduction was 23.1 ± 14.3% at last follow-up visit. Considering unadjusted post-laser IOP values, it was found a 20% greater absolute IOP reduction (median [interquartile range] 6 mmHg [4–7] vs 5 mmHg [3–7]; p = 0.04), with a success rate of 76%. Although baseline IOP was significantly associated with both adjusted and unadjusted post-laser IOP reduction, a stronger association was found when unadjusted IOP values were considered (p < 0.001 and R² = 0.35; p < 0.001 and R² = 0.67, respectively). Age, mean deviation (MD) index, central corneal thickness and type of glaucoma were not significant predictors (p ≥ 0.150).

Conclusions: In this group of patients with early OAG or ocular hypertension, our short-term results confirmed SLT as a safe and effective alternative for IOP reduction. Although better outcomes were found in eyes with higher preoperative IOP, this effect was mitigated when results were adjusted to the fellow untreated eye (to the influence of between visits-IOP fluctuations).

Keywords: Selective laser trabeculoplasty, Intraocular pressure, Fellow eye, Open-angle glaucoma, Treatment
Background

Glaucoma is one of the most common optic neuropathies, characterized by progressive retinal ganglion cells loss, changes in the appearance of the optic disc and visual field damage [1]. Until nowadays, elevated intraocular pressure (IOP) remains the major known risk factor for glaucoma development and progression [2, 3]. Several large randomized clinical trials underscored that the only proven method to treat glaucoma is the reduction of the IOP toward a target level that will avoid functional impairment by slowing the rate of disease progression [2, 4–6]. Usually, the initial target aims for a 20 to 50% reduction on pressure, depending on baseline IOP values, disease stage and patient’s life expectancy [7]. Depending on the progression of the disease, the target pressure may need to be readjusted during follow-up [7]. Intraocular pressure may be lowered by using topical medications, incisional surgery, or laser procedures [7]. When it comes to laser surgery, the two main options available are argon laser trabeculoplasty (ALT) and selective laser trabeculoplasty (SLT) [8].

Latina and coworkers have introduced SLT in 1995, providing us with a safe and effective non-invasive treatment modality for patients with open-angle glaucoma (OAG) and ocular hypertension (OH) [9, 10]. SLT lowers IOP by inducing biological changes in the trabecular meshwork resulting in increased aqueous outflow [9, 10]. It is performed with a Q-switched Nd:yttrium-aluminum-garnet (YAG) laser (λ = 532 nm), that delivers short burst of low-fluence laser energy to selected melanin-containing cells in the trabecular meshwork, causing intracellular targeting of the pigmented trabecular meshwork cells without damage to adjacent no pigmented cells or structures [9].

Several studies with follow-up ranging from 4 weeks to 72 months demonstrated the efficacy of SLT as an IOP lowering modality, with an average success rate of 70% [10–13]. Some recent data have suggested SLT as initial therapy, especially for eyes with early disease or high-risk OH [14]. Although substantial IOP reductions can be achieved in the majority of patients, the final SLT effect may vary significantly between patients. As approximately 30% of the patients do not respond to SLT therapy, it would be important to identify predictors of success [10–13].

In few previous reports that investigated factors associated with the magnitude of IOP reduction following SLT, the only significant predictor that has been consistently documented is baseline IOP (it is not clear until now whether this association could in part just be an effect of regression to the mean [15–17]) [10–13]. As these studies did not focus specifically on eyes with early glaucoma and most importantly did not adjust post-laser IOP results to the influence of between visits-IOP fluctuations, [10–13] we sought to determine success predictors and to study the role of the fellow untreated eye as a covariable for adjustment of IOP outcomes following SLT in early OAG or ocular hypertension patients.

Methods

This case series study adhered to the tenets of the Declaration of Helsinki and was approved by the Institutional Review Board of the Federal University of São Paulo. Additionally, written informed consent was obtained from all participants.

Study participants

We prospectively enrolled patients with uncontrolled early OAG or OH (inadequate IOP control requiring additional treatment). All participants underwent a complete ophthalmological examination including review of medical history, best-corrected visual acuity, IOP measurement with Goldmann applanation tonometry (Haag-Streit, Koeniz, Switzerland), slit-lamp biomicroscopy, gonioscopy, refraction and dilated fundus examination. Key Exclusion criteria were previous glaucoma surgery, history of ocular trauma or inflammation, and visual field mean deviation (MD) index worse than -6 decibels (dB).

All patients had early OAG or OH with uncontrolled IOP (individualized for each patient, based on the level of glaucomatous damage and/or based on disease progression [visual field progression confirmed by at least three visual field test or structural damage confirmed by stereophotograph]); age >18 years and no previous laser or incisional glaucoma surgery.

The definition of OAG was based on the presence of repeatable (≥2 consecutive) abnormal standard automatic perimetry (SAP) test results on the 24-2 program of the visual field (Humphrey Field Analyzer; Carl Zeiss Meditec, Inc) or if progressive glaucomatous optic disc changes were noted on masked examination of stereo photographs, regardless of the results of SAP. We defined abnormal SAP results as those with a pattern standard deviation index outside the 95% confidence limits or glaucoma hemifield test results outside the reference range. Early glaucoma was defined as characteristic OAG and reproducible visual field loss, with visual field mean deviation index better than -6 dB [18]. OH was defined as of IOP higher than 21 mmHg, with healthy-appearing optic discs and without repeatable abnormal SAP results. OH had at least three IOP measurements in each eye at pre-laser time points.

Selective Laser Trabeculoplasty (SLT)

All participants underwent SLT (one single laser session) performed by the same surgeon in a standardized
fashion. The same preoperative medical regimen was maintained during follow-up for all patients. Post-treatment assessments were scheduled at week 1 and months 1, 2, and 3. The IOP was measured with a Goldmann Tonometer.

All patients underwent one session of SLT using a frequency-doubled Q-switched Nd:YAG laser (Laserex Tango™ Nd:YAG, Ellex Medical, Australia) emitting at 532 nm with pulse duration of 3 nanoseconds and a spot size of 400 μm coupled to a slit-lamp delivery system. A Goldmann 3-mirror goniolens was placed on the eye with 1% methylcellulose. The aiming beam was focused onto the pigmented trabecular meshwork. The 400 μm spot size was large enough to irradiate the entire anteroposterior height of the trabecular meshwork. In all eyes, approximately 100 adjacent but nonoverlapping laser spots were placed over 360° of the trabecular meshwork. Initial energy level was set to 0.80 mJ and changed according to the level of trabecular meshwork pigmentation. The end point of each laser application was minibaba bubble formation. Brimonidine 0.2% was instilled before and after the procedure, and 0.1% dexamethasone acetate was administrated 4 times a day for 5 days in all patients.

Data collected included age, gender, race, type of OAG, visual field status, preoperative (average of 3 separate measurements) and postoperative IOP, number of antiglaucomatous medications, gonioscopy appearance, pachymetry, surgical complications, and any subsequent related event.

**Statistical analysis**

Descriptive statistics included mean and standard deviation values for normally distributed variables, while those not normally distributed were presented with median and interquartile range. Skewness/Kurtosis tests and histograms were used to check Normality. Paired t-test was used for comparison of IOP values between each time point (baseline and post-laser treatment). For non-normally distributed variables we used a non-parametric test (Wilcoxon rank-sum test).

In order to account for possible influence of IOP fluctuation on laser outcomes, post-laser IOP values of the treated eye of each patient were also analyzed adjusting for IOP changes (between visits variation) of the untreated fellow eye (adjusted analysis). Factors associated with the magnitude of IOP reduction were investigated using multiple regression analysis.

All statistical analyses were performed with commercially available software (MedCalc software; MedCalc, Inc., Mariakerke, Belgium). The α level (type I error) was set at 0.05.

**Results**

A total of 45 eyes of 45 patients were enrolled. Among these patients, 32 (72%) had primary OAG, 4 (9%) had pigmentary glaucoma, 6 (13%) had OH, and 3 (6%) had exfoliative glaucoma. Mean age and average SAP MD for this sample were 57.6 ± 11.7 years and -2.3 ± 1.8 dB, respectively. Demographic and clinical data of these patients are presented in details in Table 1. According to the Spaeth grading of pigment on the trabecular meshwork, [19] 70% patients had moderate pigmentation (PTM ++, from PTM + to PTM ++++) and all patients had open angle (visible until at least the scleral spur in all quadrants during the gonioscopy). Table 2 shows details about mean IOP in each post-treatment assessment.

Adjusted success rate (defined as IOP reduction ≥ 20%) was 64% and mean percentage of IOP reduction was 23.1 ± 14.3% at last follow-up visit. Figure 1 shows for adjusted success rate, the mean IOP at baseline and last follow-up visit. Considering unadjusted post-laser IOP values, it was found a 20% greater absolute IOP reduction (median [interquartile range] 6 mmHg [4–7] vs 5 mmHg [3–7]; p = 0.04), with a success rate of 76%. Figure 2 shows for unadjusted success rate, the mean IOP at baseline and last follow-up. And Table 3 summarizes the laser outcomes for adjusted and non-adjusted success rate.

In the univariable regression analysis, although baseline IOP was significantly associated with both adjusted and unadjusted post-laser IOP reduction, a stronger association was found when unadjusted IOP values were

| Table 1 Demographic and clinical variables of study patients (n = 45) |
|-----------------------------|--------------------------|
| Characteristic              | Value (%)                |
| Age (±SD), years            | 57.6 ± 11.7              |
| Gender, %                   | M (47%), F (53%)         |
| Race, %                     | W (75%), A (6%), B (12%), M (7%) |
| Type of Glaucoma, %         | POAG (72%), OH (13%), PG (9%), EG (6%) |
| Baseline mean IOP (±SD), mmHg | 20.8 ± 5.1 (range 12 to 39) |
| Non-adjusted post-laser mean IOP (±SD), mmHg | 14.98 ± 2.89 (range 10 to 22) |
| Adjusted post-laser mean IOP (±SD), mmHg | 15.71 ± 4.06 (range 7 to 31) |
| Number of Medications (±SD) | 1.4 ± 1.2 (range 0 to 4) |
| Average SAP MD (±SD), dB    | -2.3 ± 1.8 (range -5.9 to 0.4) |
| Pachymetry (±SD), μm        | 520.8 ± 426.4 (range 444 to 624) |

Abbreviations: SD standard deviation, M male, F female, W white, A Asian, B Black, M Mixed, IOP intraocular pressure, mmHg millimeter of mercury, POAG primary open angle glaucoma, OH ocular hypertension, PG pigmentary glaucoma, EG exfoliative glaucoma, SAP standard automatic perimetry, MD mean deviation
considered \( p < 0.001 \) and \( R^2 = 0.35 \); \( p < 0.001 \) and \( R^2 = 0.67 \); respectively.

In the multiple regression analysis, the only factor significantly associated with the magnitude of IOP reduction (adjusted values) was baseline IOP \( (p < 0.001 \) and \( R^2 = 0.46 \)). Figure 3 illustrates the relationship between the magnitude of IOP reduction (adjusted values) and baseline IOP. Age, MD index, central corneal thickness, type of glaucoma and number of medications at the baseline were not significant for this model \( (p \geq 0.150) \).

During the follow-up visits, one patient developed sustained IOP rise \( \geq 10\% \) IOP increase in 2 consecutive visits). There were no cases of peripheral anterior synechiae development or any other serious complication. Finally, three patients had sustained high IOP \( \geq 21 \) mmHg after 3 months follow-up). Mean age and average SAP MD for these three patients were 50.5 ± 6.4 years and -2.1 ± 0.4 dB, respectively. Consequently, they were treated with eye drop medications. Incisional surgery was not required for any patient. These three patients are currently being followed with no visual field progression.

**Discussion**

This study has shown that in early glaucomatous disease, SLT is safe and effective for IOP reduction. In addition, using the unadjusted analysis of post-laser IOP we tend to overestimate success rates (the influence of IOP fluctuations between the visits). To the best of our knowledge, this is the first study that provides evidence that the fellow untreated eye should be considered to allow post-laser outcomes adjustment.

Different studies have tried to determine the predictors of success for adjuvant SLT in OAG in different populations [20–25]. The different factors that have been consistently described to predict SLT success throughout the literature include: no prior antiglaucomatous medication use [22, 24, 25] and a higher baseline IOP [20, 21, 23]. This relationship between SLT success and baseline IOP has been underscored in previous publications [20, 21, 23]. Kano et al. studied 67 eyes of 67 uncontrolled OAG patients that underwent SLT and they showed that the measure of preoperative IOP was the significant determinant for success [21]. Alternatively, Damji et al. conducted a clinical trial with 36 eyes comparing SLT vs argon laser trabeculoplasty (ALT) and they found out that the only predictor of final IOP at 6 months was the baseline IOP [20]. In addition, in a retrospective study, Rhodes et al. observed that patients with higher preoperative IOPs had a greater reduction in IOP in both eyes [26]. In a prospective interventional study, Koucheki and Hashemi also found significant correlation between the preoperative IOP level and

| Table 2 Intraocular pressure values (mmHg) at each time point |
|-------------------------------------------------------------|
| Mean IOP (± SD) mmHg | Baseline | 1 week Post-treatment | 1 month Post-treatment | 3 months Post-treatment |
|----------------------|----------|-----------------------|------------------------|------------------------|
| 20.8 ± 5.0           | 18.8 ± 5.1 | 16.8 ± 5.4           | 15.0 ± 2.9             |

Fig. 1 Box plots showing for adjusted success rate, the mean intraocular pressure at baseline and last follow-up visit. * Box represents median and interquartile range. Whiskers correspond to maximum and minimum 1.5 interquartile range (IQR)
the IOP reduction after SLT [27]. In our study, baseline IOP was the only factor significantly associated with SLT success. Even though we have focused on eyes with early glaucoma (SAP MD better than -6 dB) or OH, our results are in agreement with those previously reported studies with glaucomatous patients with different disease stages, as they also found a positive association between baseline IOP and magnitude of IOP reduction [20, 26–28].

When we analyzed different aspects such as age, SAP MD index, central corneal thickness and type of glaucoma, no significant association was found in this present study. These findings are also in agreement with previous SLT publications that showed no correlation for sex, age, previous ocular surgery, lens status, classes of antiglaucomatous medications, angle pigmentation or type of OAG [26–29]. It is true that some studies found correlation between age and SLT success rates. For example, Ahmed et al. found that age older than 60 years was associated with greater SLT success rates and Lee et al. also described that older age was found to be a significant predictor for success (Odds Ratio: 1.11; \( p = 0.0003 \)) [30, 31]. The reason for this disagreement may be due to different characteristics of these samples. Our patients had a mean age of 57.6 years old that is higher than the other two studies.

Regarding the association between SLT outcomes and type of glaucoma, we have not found significant association in this present study. It is true that Chen et al. showed that pigmentation at the trabecular meshwork is related to the pressure-lowering effect of SLT 7 months after the SLT treatment [32]. However, according to Hodge et al., the pigmentation of trabecular meshwork and type of glaucoma did not predict better outcome [33]. The methods used by Chen et al. included 32 patients in two different groups who received SLT with 25 laser spots on 90° of trabecular meshwork, the other 32 patients who received SLT with 50 laser spots on 180° of trabecular meshwork and were followed for 7 months post-treatment [32]. Alternatively, Hodge et al. included 89 randomized patients who were followed by 12 months post-treatment [33]. Therefore, it is possible that the different methodology applicable in different studies can lead to these different results. Future studies should be necessary to evaluate the real impact of type of glaucoma and trabecular meshwork pigmentation in SLT outcomes.

In our sample, we described one case (2%) of sustained IOP rise (≥10% IOP increase in 2 consecutive visits) that resolved without additional treatment. There were no cases of peripheral anterior synechiae development or any other serious complication. This incidence is also in

| Table 3 Laser Outcomes for adjusted and non-adjusted success rates |
|----------------------|---------------|---------------|
| Variables            | Adjusted      | Non-adjusted  |
| Delta IOP (±SD), mmHg| 5.1 ± 3.8 (range -2 to 21) | 5.8 ± 3.8 (range 0 to 20) |
| Delta IOP (±SD), %   | 23.1 ± 14.3 (range -14.3 to 75) | 26 ± 12.6 (range 0 to 51.3) |
| Success Rate, %      | 64%           | 76%           |

Abbreviations: IOP intraocular pressure, SD standard deviation, mmHg millimeter of mercury
agreement with reported literature. Most reported adverse effects for SLT such as discomfort, pain or photophobia are mild and resolve within few days without treatment [34, 35]. The transient IOP rise of ≥5 mmHg occurs in 0 to 28% of eyes studied, [13, 36, 37] and ≥10 mmHg in up to 5.5% of eyes [13, 23]. It usually resolves quickly with or without topical antiglaucoma treatment, usually within 24 h. Other side effects reported in the literature are: peripheral anterior synechiae, hyphema, bilateral anterior uveitis and choroidal effusion [36, 38, 39]. There were no cases of these complications in this present study during 3-months follow-up. We also reported three patients (7%) with sustained high IOP (≥21 mmHg after 3 months follow-up). This result is not surprising, as previous studies have shown that SLT is not effective in 20–30% of the cases [13].

Moreover, the key finding of the present study was the difference between adjusted and non-adjusted post-laser results. As without accounting for the influence of IOP variation we found an overestimated lowering effect, therefore the main clinical implications of our findings is that it seems reasonable to treat one eye at a time and use the IOP values of the untreated fellow eye as controls. Probably, the association between baseline IOP and post-laser IOP results found in different previous studies is partially related to the effect of regression to the mean [15–17]. It is true that previous studies have reported a modest contralateral effect in the untreated fellow eyes of patients undergoing selective laser trabeculoplasty. Given that mechanism of effect of SLT on IOP reduction is considered to be a biological process it is possible that there is contralateral reduction in response to the SLT laser. However, this fact cannot exclude the regression to mean.

It is important to discuss some specific limitations of the present study. First, it is limited by its small sample size; however even with a small sample we found a significant difference between unadjusted analysis of post-SLT IOP and the non-adjusted one, and in addition this is the first study focused on early glaucoma patients. However, future studies should be necessary to confirm this hypothesis. Second, the 3-month IOP was used for the calculation of IOP response. A longer period following SLT would have been more ideal to estimate the real success rate. Third, topical antiglaucomatous medications were not washed out prior to SLT procedure. However, we considered unethical and inappropriate to stop antiglaucomatous medication in these patients. Additionally, as reported in the literature, the use of eye drops medication did not seem to influence SLT success significantly [28]. Lastly, we have not analyzed different aspects that could influence the SLT final results such as greater degree of spherical equivalent or more refractive error. Lee et al. recruited 51 eyes of 31 patients from Chinese population and they found that greater degree of spherical equivalent or more refractive error was a predictor of SLT success (Odds Ratio: 1.19; p = 0.02) [31]. Although this is an interesting point, this is not the main purpose of this study; therefore, future studies can be carried out from Brazilian population to elucidate this question.
Conclusions
In conclusion, our results suggest that SLT is safe and effective for IOP reduction in OHT and early OAG. Higher IOP reduction was found in those with higher pre-laser IOP. We found that success was overestimated if the post-laser IOP was not adjusted for the inter visit variation in the other eye. We, therefore suggest that, whenever possible, laser should be performed in one eye at a time thus allowing for post-laser outcomes adjustment. However, analysis of visual field progression and structural examination should be always taking into account for a better understanding of the treatment impact.

Abbreviations
ALT: Argon laser trabeculoplasty; IOP: Intraocular pressure; MD: Mean deviation; OAG: Open-angle glaucoma; OH: Ocular hypertension; SAP: Standard automatic perimetry; SLT: Selective laser trabeculoplasty; YAG: Yttrium-aluminum-garnet

Acknowledgements
None

Funding
None

Availability of data and material
Not Applicable

Authors’ contributions
Made substantial contributions to conception and design, or acquisition of data, or analysis and interpretation of data; MC, CPBG, FSL, LGB, MU, TSP. Been involved in drafting the manuscript or revising it critically for important intellectual content; MC, CPBG, FSL, LGB, MU, TSP. Given final approval of the version to be published. Each author should have participated sufficiently in the work to take public responsibility for appropriate portions of the content; MC, CPBG, FSL, LGB, MU, TSP. Agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. MC, CPBG, FSL, LGB, MU, TSP. All authors read and approved the final manuscript.

Competing interests
The authors declare that they have no competing interests.

Consent for publication
Not Applicable

Ethics approval and consent to participate
This case series study adhered to the tenets of the Declaration of Helsinki and was approved by the Institutional Review Board of the Federal University of São Paulo. Additionally, written informed consent was obtained from all participants.

Author details
1Department of Ophthalmology, Federal University of São Paulo, Rua Botucatu, 821. Vila Clementino, São Paulo, São Paulo CEP: 04023-062, Brazil.
2Glaucoma Unit, Hospital Medicina dos Olhos, Osasco, São Paulo, Brazil.

Received: 16 June 2016 Accepted: 10 November 2016
Published online: 23 November 2016

References
1. Weinreb RN, Khaw PT. Primary open-angle glaucoma. Lancet. 2004;363(9422):1711–20.
2. Kass MA, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP, Parrish 2nd RK, West SK, Wilson MR, Gordon MO. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120(6):701–13. discussion 829-730.
3. Sommer A, Tielisch JM, Katz J, Quigley HA, Gottsch JD, Javitt J, Singh K. Relationship between intraocular pressure and primary open angle glaucoma among white and black Americans. The Baltimore Eye Survey. Arch Ophthalmol. 1991;109(8):1090–5.
4. Boland MI, Ervin AM, Friedman DS, Jampel HD, Hawkins BS, Vollenweider D, Chelladurai Y, Ward D, Suarez-Cuevo C, Robinson KA. Comparative effectiveness of treatments for open-angle glaucoma: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med. 2013;158(4):271–9.
5. The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol. 2000;130(4):429–40.
6. Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M. Early Manifest Glaucoma Trial G. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002;120(10):1268–79.
7. Weinreb RN, Aung T, Medeiros FA. The pathophysiology and treatment of glaucoma: a review. JAMA. 2014;311(18):1901–11.
8. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT) and glaucoma laser trial follow-up study: 7. Results. Am J Ophthalmol. 1995;120(6):718–31.
9. Latina MA, Sibayan SA, Shin DH, Noecker RJ, Marcellino G. Q-switched 532-nm Nd:YAG laser trabeculoplasty (selective laser trabeculoplasty): a multicenter, pilot, clinical study. Ophthalmology. 1998;105(11):2082–8. discussion 2089-2090.
10. Cvenkel B. One-year follow-up of selective laser trabeculoplasty in open-angle glaucoma. Ophthalmologica International ophthalmologica International journal of ophthalmology Zeitschrift für Augenheilkunde. 2004;218(1):20–5.
11. Gracner T, Falez M, Gracner B, Pahor D. Long-term follow-up of selective laser trabeculoplasty in primary open-angle glaucoma. Klin Monatsbl Augenheilkd. 2006;223(9):743–6.
12. Weinand FS, Atthen F. Long-term clinical results of selective laser trabeculoplasty in the treatment of primary open angle glaucoma. Eur J Ophthalmol. 2006;16(1):100–4.
13. Almeida Jr ED, Pinto LM, Fernandes RA, Prata TS. Pattern of intraocular pressure reduction following laser trabeculoplasty in open-angle glaucoma patients: comparison between selective and nonselective treatment. Clin Ophthalmol. 2011;5:933–6.
14. Katz LJ, Steinmann WC, Kabir A, Molinexaur J, Wizov SS, Marcellino G, Group SLMS. Selective laser trabeculoplasty versus medical therapy as initial treatment of glaucoma: a prospective, randomized trial. J Glaucoma. 2012;21(7):460–8.
15. Shrivastava A, Singh K. The effect of cataract extraction on intraocular pressure. Curr Opin Ophthalmol. 2010;21(2):118–22.
16. Slabaugh MA, Chen PP. The effect of cataract extraction on intraocular pressure. Curr Opin Ophthalmol. 2014;25(2):122–6.
17. Parrish 2nd RK. The European Glaucoma Prevention Study and the Ocular Hypertension Treatment Study: why do two studies have different results? Curr Opin Ophthalmol. 2005;17(2):138–41.
18. Mills RP, Budenz DL, Lee PP, et al. Categorizing the stage of glaucoma from pre-diagnosis to end-stage disease. Am J Ophthalmol. 2006;141:24–30.
19. Spaeth GL. The normal development of the human anterior chamber angle: a new system of descriptive grading. Trans Ophthalmol Soc U K. 1971;91:790–9.
20. Danjii KF, Shah KC, Rock WJ, Bains HS, Hodge WG. Selective laser trabeculoplasty v argon laser trabeculoplasty: a prospective randomised clinical trial. Br J Ophthalmol. 1999;83(6):718–22.
21. Kano K, Kusuyama Y, Mizoue S, Ito N. Clinical results of selective laser trabeculoplasty. Nippon Ganka Gakkai Zasshi. 1999;103(8):612–6.
22. Melamed S, Ben Simon GJ, Levkovitch-Verbin H. Selective laser trabeculoplasty as primary treatment for open-angle glaucoma: a prospective, nonrandomized pilot study. Arch Ophthalmol. 2003;121(7):957–60.
23. Song J, Lee PP, Epstein DL, Srinett SS, Herndon Jr LW, Asrani SG, Allingham RR, Challa P. High failure rate associated with 180 degrees selective laser trabeculoplasty. J Glaucoma. 2005;14(6):532-n.
24. Rachmiel R, Trope GE, Chipman ML, Gouws P, Buys YM. Laser trabeculoplasty trends with the introduction of new medical treatments and selective laser trabeculoplasty. J Glaucoma. 2006;15(4):306–9.
25. Barkana Y, Belkin M. Selective laser trabeculoplasty. Surv Ophthalmol. 2007;52(6):534–54.
26. Rhodes KM, Weinstein R, Saltzmann RM, Aggarwal N, Kooner KS, Petroll WM, Whitson JT. Intraocular pressure reduction in the untreated fellow eye after selective laser trabeculoplasty. Curr Med Res Opin. 2009;25(3):787–96.

27. Koucheki B, Hashemi H. Selective laser trabeculoplasty in the treatment of open-angle glaucoma. J Glaucoma. 2012;21(1):65–70.

28. Mao AJ, Pan XJ, McIlraith I, Strasfeld M, Colev G, Hutnik C. Development of a prediction rule to estimate the probability of acceptable intraocular pressure reduction after selective laser trabeculoplasty in open-angle glaucoma and ocular hypertension. J Glaucoma. 2008;17(6):449–54.

29. Martow E, Hutnik CM, Mao A. SLT and adjunctive medical therapy: a prediction rule analysis. J Glaucoma. 2011;20(4):266–70.

30. ASCRS Eyeworld. Ahmed IK AD. Best Paper of Session. Individual patient factors influence SLT success. 2014. Available from: http://www.eyeworld.org/article.php?sid=2685.

31. Lee JW, Liu CC, Chan J, Wong RL, Wong FY, Lai JS. Predictors of success in selective laser trabeculoplasty for primary open angle glaucoma in Chinese. Clin Ophthalmol. 2014;8:1787–91.

32. Chen E, Golchin S, Blomdahl S. A comparison between 90 degrees and 180 degrees selective laser trabeculoplasty. J Glaucoma. 2004;13(1):62–5.

33. Hodge WG, Damji KF, Rock W, Buhrmann R, Bovell AM, Pan Y. Baseline IOP predicts selective laser trabeculoplasty success at 1 year post-treatment: results from a randomised clinical trial. Br J Ophthalmol. 2005;89(9):1157–60.

34. Mahdy MA. Efficacy and safety of selective laser trabeculoplasty as a primary procedure for controlling intraocular pressure in primary open angle glaucoma and ocular hypertensive patients. Sultan Qaboos Univ Med J. 2008;8(1):153–8.

35. Klamann MK, Maier AK, Gonnennmann J, Ruokonen PC. Adverse effects and short-term results after selective laser trabeculoplasty. J Glaucoma. 2014;23(2):105–8.

36. Abdelrahman AM, Eltanamly RM. Selective laser trabeculoplasty in Egyptian patients with primary open-angle glaucoma. Middle East Afr J Ophthalmol. 2012;19(3):299–303.

37. Shibata M, Sugiyama T, Ishida O, Ueki M, Kojima S, Okuda T, Ikeda T. Clinical results of selective laser trabeculoplasty in open-angle glaucoma in Japanese eyes: comparison of 180 degree with 360 degree SLT. J Glaucoma. 2012;21(1):17–21.

38. Babighian S, Caretti L, Tavolato M, Cian R, Galan A. Excimer laser trabeculotomy vs 180 degrees selective laser trabeculoplasty in primary open-angle glaucoma. A 2-year randomized, controlled trial. Eye. 2010;24(4):632–8.

39. Tang M, Fu Y, Fu MS, Fan Y, Zou HD, Sun XD, Xu X. The efficacy of low-energy selective laser trabeculoplasty. Ophthalmic Surg Lasers Imaging. 2011;42(1):59–63.